The purpose of the eSMART (Electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology) study is to evaluate the use of mobile phone technology to manage chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), colorectal cancer (CRC), Hodgkin's lymphoma (HL), and non-Hodgkin lymphoma (NHL)) across multiple European sites. One key objective was to review the published and grey literature on assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, HL, and NHL to ensure that ASyMS remained evidence-based and reflected current and local practice.
Introduction
In 2013, the European Union (EU) funded eSMART 1 ; a study evaluating Electronic Symptom Management using the Advanced Symptom Management System (ASyMS 2 ) mobile phone technology for the management of chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), colorectal cancer (CRC), Hodgkin's lymphoma (HL), and non-Hodgkin lymphoma (NHL)) cancers across multiple clinical sites in Europe. Developed in conjunction with cancer clinicians and people with cancer (Kearney et al., 2006 , Gibson et al., 2009 , Gibson et al., 2010 , Maguire et al., 2015 , ASyMS is a mobile phone based remote monitoring system that enables real time monitoring of CRTs through patients' completion of electronic patient reported outcome measures (ePROMs). ASyMS facilitates immediate tailored management of CRTs in the home care setting, automatic and immediate triaging of care when toxicities exceed clinical norms, and the provision of evidence-based self-care advice.
At the outset, a key objective of eSMART was to undertake a review of the published and grey literature (international, national and local clinical guidelines) related to the assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, NHL, and HL to ensure that ASyMS (risk algorithms, symptom protocols, self-care advice) was evidence-based, updated 3 , and reflected current and local practice. Consistent with the toxicities assessed and managed using ASyMS, this review was limited to the most common CRTs (i.e., nausea, vomiting, diarrhoea, constipation, mucositis/stomatitis, chemotherapy induced peripheral neuropathy (CIPN), hand-foot syndrome (palmar plantar erythrodysesthesia (PPE)), fever (or febrile neutropenia (FN)), infection, fatigue, pain). The purpose of this paper is to report on the background, objectives, methods, and key findings from the published and grey literature review.
Methods

Search Strategy (published literature)
With the assistance of a college librarian, a search strategy with five search strings (Figure 1 , Appendix 1) was designed. This search was conducted within three electronic databases (i.e., PubMed, CINAHL, PsycARTICLES) using specific Boolean operators, truncation markers, and MeSH headings. All searches were limited to English papers, involving human participants over 18 years of age, with an abstract available dating from January 1st 2004 to April 5th 2014. Given the recent literature review 3 , it was deemed sufficient to target empirical literature published within the previous ten years. The results were exported into WebEndNote© and articles were screened in two stages. First, titles and abstracts of all retrieved articles were screened for eligibility by two reviewers (CP1, AD). Where relevance was unclear from the title or abstract, a copy of the full text was obtained.
One hundred and eighty articles met the inclusion criteria (see Table 1 ) and full text versions were obtained. The second phase of screening involved assessment of the full texts (N=180) by five reviewers (CP1, AD, EF, PF, AM). Studies were selected if they met the inclusion criteria. To further ensure the quality of the included literature, articles were required to meet the criteria outlined by the UK's Department of Health (DoH) 'Typology of Supportive Evidence' (UK DoH, 2011) (Table 1) . Once all of the articles were screened, the eligibility outcomes were cross-checked and examined by a sixth reviewer (CP2). This reviewer was given 10% of the full text articles to compare her rating of outcomes with those of the original screening team. Seven discrepancies were identified and three reviewers (CP1, CP2, AD) made the final decision regarding relevance. A PRISMA diagram of the systematic review process that depicts the reasons for inclusion and exclusion criteria of articles is presented in Figure 2 .
Table 1 Eligibility guidelines for screening citations
In the context of patients diagnosed with either BC, CRC, NHL, or HL, studies which Inclusion Criteria 1. included adult patients (18+ years) 2. focused exclusively on symptom management and self-care strategies for nausea, vomiting, diarrhoea, constipation, fever (or FN), infection, CIPN, mucositis (or stomatitis), fatigue, PPE, pain 3. investigated self-care strategies (as a primary outcome) 4. involved aspects of symptom management and/or assessment conducted by clinicians 5. reviewed the use of complementary and alternative medicine (CAM) therapies that were relevant to self-care of the symptoms of interest Exclusion Criteria 1. focused on the experience (or prevalence) of symptoms with no reference to management or self-care 2. reported results of CAM therapies 3. focused on patients with Burkitt's lymphoma; patients < 18 years; patients in survivorship following chemotherapy completion; patients with metastatic disease and in the context of palliative care; patients undergoing bone marrow transplantation (BMT) 4. reported validation of tools 5. focused on symptoms not listed in the inclusion criteria 6. investigated the use of medicinal products to treat or manage CRTs Typology of the level of evidence (adapted from UK Department of Health) Included Papers A1 Systematic reviews which included at least one randomised controlled trial (RCT) (e.g. Systematic Reviews from Cochrane or Centre for Reviews and Dissemination).
A2 Other systematic and high quality reviews which synthesise references. Once the final set of relevant papers were identified (N=27), key data were extracted and tabulated (see Appendix 2).
Figure 2. Screening process
Methods adopted to review the grey literature
This scoping review included a focused appraisal of the relevant grey literature to minimise the omission of important information which is not published (Blackhall and Ker, 2007) . This approach included a review of symptom management protocols across the participating clinical sites (N=13) in the study to achieve consistency with reference to the symptom management and self-care advice utilised for ASyMS. More specifically, relevant clinical practice guidelines (CPGs)/evidence-based resources (EBRs) from the main international medical and nursing cancer organisations were reviewed (i.e., the European Society for Medical Oncology (ESMO), the American Society for Clinical Records identified through database searching Symptom Management (n = 5,596) Self-Care = (n = 1,672)
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Results
The findings from this review are structured around each of the symptoms, that is, each symptom is discussed with reference to the relevant published and grey literature. For the published literature, the initial search strategy elicited 7,268 unique publications. After a full-text screening process, 27 publications were included in this review. The majority of the papers were either reviews (n=7, including four systematic reviews (SR)) or RCTs (n=7). With the exception of a single arm pilot study, the remaining studies were descriptive utilising a quantitative (n=9), qualitative (n=2), or mixed methods (n=1) approach (Appendix 2). The majority of the papers (n=14) addressed fatigue (either as a primary or secondary endpoint in intervention studies or in addition to other symptoms in the reviews and descriptive studies) and these papers primarily focused on patients with BC. Nine papers addressed multiple symptoms while CIPN was the focus of three papers. Chemotherapyinduced nausea and vomiting (CINV) were addressed separately in two papers and together in one paper. Oral mucositis (OM) and pain were both the focus of two separate papers. None of the papers focused on symptom management for diarrhoea, constipation, or PPE. The majority of the studies addressed various interventions for symptom management. Only three papers (Chou et al., 2007 4 , Speck et al., 2012 , Spichiger et al., 2012 addressed self-care strategies.
Relevant CPGs/EBRs were found for fatigue (n=4), CINV (n=5), OM (n=4), CIPN (n=3), diarrhoea (n=2), constipation (n=2), FN/neutropenic sepsis/infection (n=7), PPE (n=1), and pain (n=4) (Appendix 3, Tables 4-12, inclusive). Information on symptom management protocols and self-care guidance was provided by over 40% of the participating clinical sites (sites did not have the protocols/guidance available in English and/or did not have institution-specific guidelines) (Tables 3-12, inclusive) .
Fatigue
The review of the published literature found 14 papers on fatigue. Ten of these studies focused on various fatigue-related symptom management interventions. However, with the exception of one study that evaluated the effect of exercise on patients with lymphoma (Courneya et al., 2009) , the others focused on fatigue in BC. None of the studies addressed symptom management interventions (other than self-care) for fatigue in CRC. More specifically, this review found two multicentre RCTs (Courneya et al., 2007a , Courneya et al., 2007b , Courneya et al., 2013 and one single arm pilot study (Ligibel et al., 2010) that focused on the impact of exercise for the management of fatigue in women receiving adjuvant treatment for BC .
Although initially, neither aerobic exercise training (AET) nor resistance exercise training (RET) significantly improved fatigue levels over usual care, positive trends were noted for both exercise groups (Courneya et al., 2007a) . Moreover, a six month post-intervention follow-up of the same study (Courneya et al., 2007b) reported improved levels of fatigue (p=.013) for patients who confirmed adherence to both AET and RET. Ligibel and colleagues (2010) reported a trend toward improved fatigue levels in a similar cohort of patients who completed a home-based, 12 week moderate-intensity aerobic exercise intervention with telephone counselling. More recently, Courneya et al. (2013) reported that a higher dose (50-60 minutes) of aerobic or combined exercise (aerobic and resistance) were both feasible and safe for patients receiving adjuvant chemotherapy for BC and may be superior to standard doses (25-30 minutes) for managing symptoms such as fatigue.
The benefit of exercise for the management of fatigue both during and after treatment for BC was highlighted in three reviews (two SR (Kirshbaum, 2006 , Wanchai et al., 2011 and one nonsystematic but comprehensive review (Loprinzi et al., 2008) ). Wanchai and colleagues (2011) suggested that other interventions such as education and counselling, sleep therapy, and complementary therapy (CT) were likely to be beneficial for managing fatigue in BC. Courneya et al. (2009) evaluated the impact of 12 weeks of supervised AET versus usual care for patients with HL and NHL, receiving chemotherapy or no treatment. According to the authors, the AET group had superior effects for outcomes including fatigue (p=.013).
Only one study (Spichiger et al., 2012) explicitly addressed self-care strategies used to decrease cancer-related fatigue. According to the authors, patients with lymphoma, BC, CRC, and lung cancer employed various intuitive self-care approaches (most often rest) to manage their fatigue although they had difficulty explaining their rationale for the approaches chosen or whether or not they were effective. In addition, Spichiger et al. (2012) found that while patients reported that they were well informed about fatigue by clinicians on commencing chemotherapy, virtually no fatigue management support was provided during chemotherapy. Chou et al. (2007) reported on self-care strategies used for chemotherapy-induced fatigue 4 .
Four cancer organisations developed fatigue specific CPGs/EBRs, namely, UKONS (2013), ASCO (Bower et al., 2014) , ONS (Mitchell et al., 2007 , ONS, 2014 , and the NCCN (2014) ( Table 4 ). The ASCO (2014) guideline was developed to address fatigue in adult cancer survivors following completion of primary therapy. Focused on patients who present as an emergency/unplanned admission, the UKONS (2013) guideline is more relevant for the initial rather than the long term management of fatigue. That said, all of the guidelines are broadly consistent with reference to fatigue assessment and management. In terms of assessment, the guidelines highlight the importance of regular screening for fatigue and the utilisation of assessment tools and comprehensive history taking to identify fatigue and treatable contributing factors. Similarly, the symptom management strategies recommended for fatigue are broadly consistent, including exercise, treatment of contributing factors, various psychoeducational interventions, cognitive behavioural therapy (CBT)/behavioural therapy (BT), CT and if necessary medications such as psychostimulants.
Guidelines for fatigue assessment and management were only available from one clinical site and were for the purpose of telephone triage (Table 4 ). Although more focused in nature, the assessment and management of fatigue outlined in these guidelines was congruent with those of the international cancer organisations although they do not explicitly identify exercise as an intervention. A protocol followed by three clinical sites recommended that patients with BC who are experiencing fatigue should, where appropriate, receive a referral to rehabilitation specialists for guidance on rest and exercise. Of note, this protocol addressed the assessment and management of issues related to BC in general, rather than to fatigue specifically.
CINV
While acknowledging that they are separate phenomena (Grunberg, 2004) , nausea and vomiting are discussed together within this context given the limited number of primary studies identified in the published literature for either toxicity. In total, six papers addressed either nausea or vomiting or both (primarily in BC). However, only two of these papers discussed symptom management interventions. In 2008, Lee et al. conducted a secondary analysis of data from a longitudinal, multicentre, RCT that examined the effectiveness of a systematic exercise intervention during and after adjuvant BC treatment. According to the authors, patients who exercised had significantly less intense nausea on completion of treatment than patients who did not exercise. Following their Cochrane review on the effect of herbal medicines on CRTs in patients with CRC, concluded that patients receiving Huangqi decoctions were less likely to develop CINV. However, the available studies were limited and of low quality. Only one study (Chou et al., 2007) addressed selfcare strategies for nausea 4 .
A number of cancer organisations developed CPGs/EBRs on CINV, including the ONS (Tipton et al., 2007 , ONS, 2014 , ESMO/MASCC , ASCO (Basch et al., 2011 ), UKONS (2013 , and the NCCN (2014) ( Table 5 ). CINV protocols were available from five clinical sites. Self-care advice only, was provided by a sixth site. In general, CPGs/EBRs focused more on the prevention and management of CINV than on assessment although the UKONS (2013) guideline did address assessment. The local protocols highlighted the importance of identifying the extent of the CINV, as well as the patients' hydration and nutritional status with a view to determining the grade of CINV and the subsequent action required. General agreement existed across the CPGs/EBRs and local protocols that CINV prevention is the first step. Similarly, the approach to treatment based on the emetogenic potential of the cytotoxic regimens is broadly consistent. For example, with the exception of UKONS, which did not focus on specific pharmacological treatments, all of the other organisations advocated that patients receiving highly emetic chemotherapy (HEC) regimens should receive the three-drug combination of a neurokinin 1 (NK1) antagonist, 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and dexamethasone with/without a benzodiazepine. According to the NCCN guideline (2014), an olanzapine based regimen may be considered as an alternative in this context. In terms of advice and self-care, general agreement existed around the importance of reviewing the prescribed anti-emetic regime with patients and counselling them regarding hydration and nutrition. The ONS (2007 ONS ( , 2014 , ESMO/MASCC (2010) and three clinical sites guidelines suggested the potential benefit of non-pharmacological therapies such as relaxation/progressive muscle relaxation. The guidelines from ESMO/MASCC and ASCO considered the importance of approaches such as BT with desensitisation for anticipatory CINV.
OM
Two of the papers from the published literature review addressed OM. However, only one focused on symptom management. Peterson and colleagues (2009) evaluated the safety and efficacy of high and low dose recombinant human intestinal trefoil factor (rhITF) as a topical oral spray for the prevention and treatment of OM in patients receiving their first cycle of chemotherapy for CRC. According to the authors, high and low dose rhITF significantly reduced the incidence and severity of OM with particular improvements observed one to two weeks following treatment initiation. However, the low incidence of grade 3 and 4 OM in the study was noted and it was acknowledged that the benefits of this intervention could only be inferred for these high risk groups. Only one study (Chou et al., 2007) addressed self-care strategies for OM 4 .
Five cancer organisations developed CPGs/EBRs for OM, namely, ESMO (Peterson et al., 2011 ), UKONS (2013 , MASCC/ISOO (International Society of Oral Oncology) (Lalla et al., 2014) , and ONS (Harris et al., 2008) . Symptom protocols were available from five clinical sites (Table 6 ). Self-care advice only was provided by a sixth site. The symptom protocols addressed the prevention, assessment, and management of OM, while the CPGs/EBRs primarily focused on prevention and management. The protocols emphasised the importance of conducting a comprehensive assessment to identify the severity of OM, the presence of pain and/or other symptoms suggestive of local or systemic infection, dehydration, or compromised nutrition. With reference to management, in the main, broad agreement existed across the clinical site protocols and the CPGs/EBRs. Nonetheless, there were some variations. The use of oral care protocols and good oral hygiene in the context of OM was highlighted across all of the guidelines. However, the MASCC/ISOO (2014) guideline noted, that based on the available evidence, it is only possible to 'suggest' rather than 'recommend' the use of oral care protocols for OM prevention, while no guideline is recommended for the use of oral care protocols for OM treatment. In addition, although saline/sodium bicarbonate mouthwashes were recommended by other organisations (ONS, 2008 , ESMO, 2011 , MASCC/ISOO indicated that no guideline has been developed in this context due to insufficient and/or conflicting evidence. Some divergence was found with respect to the use of sucralfate mouthwash which is recommended by UKONS (2013) and four clinical sites. However, the MASCC/ISOO panel recommended against the use of sucralfate mouthwash for OM prevention or treatment based on a lack of benefit identified in the studies reviewed. In addition, the ONS and ESMO did not recommend the use of sucralfate for OM treatment associated with radiotherapy. Differences in recommendations were not just confined to those between international, local, and national guidelines. Although the MASCC/ISOO panel 'suggest' (p. 1457) that doxepin 0.5% mouthwash may be effective for OM associated pain, the ONS assigned this mouthwash to the category of 'effectiveness not established'.
CIPN
Only three of the papers from the published literature review addressed symptom management and one explored self-care strategies for CIPN. Wang et al. (2007) reported that oral glutamine significantly reduced CIPN incidence and severity in patients receiving oxaliplatin for metastatic CRC. However, following a literature review, Amara (2008) concluded that more high quality RCTs were needed to assess the safety and efficacy of oral glutamine before it could be recommended for CIPN prevention in patients receiving either high dose paclitaxel or oxaliplatin. Focusing only on premenopausal patients with BC, Loprinzi et al. (2008) noted the dearth of literature on effective treatments for CIPN. Speck et al. (2012) reported that various self-care strategies were employed by women with BC to manage CIPN. While it was not possible to establish their effectiveness, the authors reported that patients focused on exercise, mindfulness, occupational therapy, and environmental planning to manage their CIPN. Although not described, Chou et al. (2007) noted that self-care strategies were used for CIPN by participants in their study 4 . (Table 7) . A symptom management protocol for CIPN was only available from one clinical site and this protocol focused primarily on assessment as it was developed for telephone triage. All of the CPGs/EBRs focused more on CIPN management than assessment although EONS outlined some important considerations for assessment. No agent was recommended for CIPN prevention. However, for CIPN treatment, ASCO (2014) suggested that clinicians 'may offer' (p.23) duloxetine while the ONS considered duloxetine as 'likely to be effective'. ASCO, ONS, and EONS all identified a number of agents which should not be used for either the prevention or treatment of CIPN based on the evidence to date. However, given the limited options for managing CIPN, ASCO noted that some agents such as tricyclic antidepressants (TCAs) and gabapentin may be reasonable to try in selected patients following a discussion regarding the research to date, benefits, harms, costs, and patient preferences.
Diarrhoea
None of the articles from the published literature review addressed symptom management interventions or self-care strategies for diarrhoea (as a primary outcome) in patients receiving chemotherapy for any of the cancers. In contrast, diarrhoea was well addressed in the grey literature. Both ONS (Muehlbauer et al., 2009 , ONS, 2014 and UKONS (2013) developed guidelines for diarrhoea, while protocols for diarrhoea were available from five clinical sites (Table 8 ). An additional clinical site provided self-care information only. UKONS addressed the initial assessment and management when patients present with diarrhoea as an emergency/unplanned admission. The ONS (2009, 2014) EBR identified interventions for both chemotherapy and radiotherapy-induced diarrhoea. Although the level of detail varied across the international and local guidelines, in general, consistency was found with reference to diarrhoea assessment and management. More specifically, all of the guidelines convey the importance of doing a comprehensive history to ascertain the extent of the diarrhoea, associated symptoms, hydration status, and treatment to date in order to determine the grade of diarrhoea and the subsequent action required. Loperamide was recommended for diarrhoea management across all of the guidelines and the importance of adherence was emphasised. The use of octreotide was recommended by both UKONS and ONS and three of the clinical sites protocols. However, although codeine phosphate was identified by UKONS (2013) and five clinical site protocols as a treatment for diarrhoea, it was not identified by ONS (2009 ONS ( , 2014 as an intervention that is 'recommended for practice', 'likely to be effective' or under 'expert opinion'. Also, ONS assigned budesonide to the 'effectiveness not established' category. However, budesonide does feature in the protocols of four clinical sites for the treatment of severe diarrhoea. In relation to self-care, broad agreement was found regarding the recommendations for hydration and nutrition.
Constipation
The published literature search located no articles on symptom management interventions for constipation (as a primary outcome) in patients receiving chemotherapy for any of the cancers. Only one study (Chou et al., 2007) addressed self-care strategies for constipation 4 .
Only a limited number of guidelines and symptom protocols were available for constipation. These documents included the UKONS (2013) guideline for the initial management of constipation in patients who present as an emergency/unplanned admission and the ONS (Woolery et al., 2008 , ONS, 2014 EBR for the prevention and management of constipation (Table 9 ). Only one clinical site provided a symptom protocol (telephone triage) for constipation, although information on self-care for this symptom was available from three additional sites. The guidance from ONS (2008) and UKONS (2013) and the clinical site protocol are broadly consistent with respect to constipation assessment. Likewise, the guidance for constipation management (including self-care) was similar. Specific information included the importance of a high fibre diet, adequate hydration, and adherence to prescribed medications. ONS (2008 ONS ( , 2014 identified a number of interventions that were considered to be 'likely to be effective' particularly in the context of opioid-induced constipation.
PPE
None of the articles retrieved through the published literature review addressed symptom management interventions or self-care strategies for PPE (as a primary outcome) in patients receiving chemotherapy for any of the cancers. No international CPGs were available for PPE. However, the ONS (2014) included this symptom in its EBR on skin reactions. The UKONS (2013) guideline focused on the initial management of patients with PPE who present as an emergency/unplanned admission (Table 10) . A symptom management protocol for PPE was only available from one clinical site and this protocol focused on management only. The UKONS (2013) guideline recommended the provision of reassurance and reinforcing the importance of the skin care regime to patients experiencing grade 1 PPE while advising to withhold treatment for higher grade PPE. Consideration of pyridoxine was recommended by both UKONS and the clinical site protocol. However, this medication was assigned to the category of 'not recommended for practice' by ONS.
FN and/or infection
FN and infection are discussed together in this context given their close relationship and the limited number of studies identified for either toxicity. The published literature search located two review papers related to these toxicities. One paper focused on the use of supportive therapies for the management of FN and infection. A second paper discussed the evidence to date for Chinese herbal medicines ( concluded that extracts containing Huangqi had favourable effects on white blood cells, with respect to both total counts and in specific subcategories of immunocompetent lymphocytes. However, the available studies were limited and of low quality. None of the studies addressed self-care for FN or infection.
A number of CPGs/EBRs were available for FN and infection (Table 11 ). ASCO (Smith et al., 2006 , Flowers et al., 2013 published guidelines on the use of CSFs and the antimicrobial prophylaxis and outpatient management of FN, respectively. Each year, the NCCN updates its guidelines for the prevention and treatment of cancer-related infections and their recommendations for myeloid growth factors. ESMO published guidelines for the management of FN (de Naurois et al., 2010) and the use of CSFs (Crawford, Caserta and Roila, 2010) . Finally, ONS produced an EBR of interventions to prevent cancer-related infections (Zitella et al. 2006 , ONS, 2014 . The UKONS (2013) guideline focused on the initial assessment and management of patients presenting with neutropenic sepsis. Symptom protocols were developed by the clinical sites for the assessment and management of FN and/or neutropenic sepsis (Table 11) . Overall, the guidance across all of these guidelines and protocols is consistent for both the assessment and management of patients presenting with FN/suspected neutropenic sepsis. All of the guidelines conveyed the importance of a comprehensive history and assessment and the administration of appropriate treatment based on the risk category identified. Broad consistency existed with respect to the prophylactic measures recommended for infection prevention.
Pain
Two papers from the published literature review focused on symptom management interventions for cancer pain. Both papers address exercise for pain in women receiving treatment for BC. Following their SR, Tatham and colleagues (2013) concluded that exercise may decrease shoulder pain related to BC treatment. However, they noted that more high quality studies were needed. Due to the limited detail in the studies reviewed, the authors could only infer that a 'multi-factorial' (p.329) exercise programme may be beneficial. Following their multicentre RCT that examined the impact of exercise on physical functioning and symptoms such as 'bodily pain' (p.1823), Courneya et al. (2013) reported that a higher dose (50-60 minutes) of aerobic exercise was more beneficial for managing bodily pain associated with adjuvant BC treatment than either standard doses (25-30 minutes) or a combined dose of 50 to 60 minutes of aerobic and resistance exercise. Only one study (Chou et al., 2007) addressed self-care strategies for pain 4 .
Cancer pain is well addressed in the grey literature. Guidelines focusing on cancer pain were available from ESMO (Ripamonti et al., 2012) , EONS (2012), ONS (Aiello-Laws et al., 2009 , ONS, 2014 and NCCN (2014) ( Table 12 ). Only one clinical site provided a pain management protocol. As this protocol was developed for telephone triage, its primary focus was pain assessment rather than pain management interventions (Table 12 ). Brief self-care advice was available from another clinical site. A general consensus was found across all of the international guidelines regarding the approach to pain assessment and management. More specifically, the guidelines highlighted the importance of undertaking a comprehensive history and assessment to examine the physical and psychosocial impact of pain. Many factors require consideration in order to determine the most appropriate interventions including but not exclusive to the type and severity of pain, whether it is acute, chronic, or breakthrough pain, the patient's diagnosis and treatment to date, comorbidities and psychosocial factors. Recommendations included the use of both pharmacological and nonpharmacological strategies and the importance of managing common side effects such as constipation and nausea and vomiting. These guidelines were broadly in line with the World Health Organisation (WHO) analgesic ladder which advocates a sequential progression from non-opioids to weak opioids to strong opioids. However, while acknowledging that the WHO ladder has served as an excellent teaching tool, NCCN suggested the use of opioids for all levels of pain including mild pain. The importance of providing psychosocial support and education to the patient and family was recommended.
Discussion
To our knowledge this scoping review is the first of its kind to examine the literature and international, national, and relevant local guidelines for the assessment and management of the most common CRTs, namely, fatigue, nausea, vomiting, OM, CIPN, diarrhoea, constipation, FN, infection, PPE, and pain in people with BC, CRC, NHL, or HL. A number of observations are evident from this review. Of all of the symptoms included in the review, fatigue is the most frequently studied with over half of the published articles addressing this symptom. However, the papers primarily focused on fatigue in women with BC. Only one study (Courneya et al., 2009 ) examined the impact of exercise in patients with lymphoma. With the exception of self-care (Spichiger et al. 2012) , none of the studies examined interventions for fatigue in patients with CRC. Given the benefits of exercise identified in the studies of BC in this review and more recently (Mishra et al., 2014) , similar studies in patients with CRC and lymphomas are warranted. In the meantime, given the relatively low engagement in exercise among oncology patients receiving chemotherapy (Spichiger et al., 2012) and among cancer survivors (Forbes et al., 2015) , clinicians should counsel patients on the benefits of exercise as tolerated.
The use of aerobic and resistance exercises are supported by ASCO, ONS, and NCCN as interventions for fatigue. The other interventions supported by these organisations and the published literature (Wanchai et al., 2011) include the management of associated symptoms and treatable factors, education and counselling, energy conservation measures, CBT/BT, sleep therapy, psychoeducational therapies, CT, and nutritional advice. However, it is likely that these interventions are only effective if assessment and management of fatigue is undertaken regularly throughout patients' treatment and not just at the outset (Spichiger et al., 2012) . While we cannot confirm that the lack of protocols from the clinical sites necessarily indicates that fatigue assessment and management is not ongoing, it does suggest that this symptom may not be prioritised to the same extent as others for which protocols do exist. If this is the case, it needs to be redressed given that fatigue is one of the most frequently reported CRTs (Goldstein et al., 2012 , Wang et al., 2014 and is associated with significant morbidity and utilization of healthcare resources (Goldstein et al., 2012) .
In contrast to fatigue, CINV was more likely to be addressed by clinical site protocols than the published literature. Both nausea and vomiting are well addressed by CPGs/EBRs including ONS, ESMO/MASCC, ASCO and NCCN guidelines. General consensus exists across these guidelines with respect to the anti-emetics recommended, with all of the organisations recommending that patients receiving HEC should receive a similar three-drug combination of anti-emetic therapy. The self-care measures recommended in the clinical site protocols are broadly consistent with those in the CPGs.
Only two papers in the review of the published literature focused on OM. However, OM guidelines are available from a number of cancer organisations and clinical sites. While a general consensus was found across all of the guidelines and protocols with respect to the assessment, management, and prevention of OM, some differences were identified in the recommendations. Although the MASCC/ISOO (2014) panel do not actively recommend against the use of oral care protocols or saline/sodium bicarbonate mouthwashes, they appear less compelled by the evidence for these interventions for the prevention of OM across all cancer treatments. However, the MASCC/ISOO (2014) panel did recommend against the use of sucralfate mouthwash for the prevention or treatment of OM. In addition, the ONS (2008, 2014) recommended against the use of sucralfate as did ESMO for the treatment of OM associated with radiotherapy. Clinical protocols from four clinical sites and the UKONS (2013) guideline on OM suggest that sucralfate was still recommended for OM. As the international guidelines were published more recently, it is conceivable that national and local protocols had not been updated to reflect these recommendations. Differences in recommendations were not just confined to those between international, national and local guidelines as evidenced by the differing recommendations from MASCC/ISOO and the ONS on the effectiveness of doxepin 0.5% mouthwash for OM associated pain. While differing conclusions may be based on the availability of data at the time of the respective guideline publications, it does underscore the challenges encountered by clinicians when updating local protocols.
CIPN was the subject of three papers in the review of the published literature. However, more studies are needed to identify effective approaches to prevent and manage this CRT. Although CPGs/EBRs were available from three international organisations, a CIPN symptom protocol was available from only one clinical site. Again, this finding may be due to the fact that the CPGs/EBRs are more recent. It may reflect the limited options available for the prevention and/or treatment of CIPN. In addition to duloxetine, ASCO suggested that TCAs and gabapentin may be reasonable to try in selected patients. The EONS (2012) guideline may be of particular benefit to oncology nurses for the purpose of educating patients about beneficial CIPN self-care strategies.
The published literature search located no papers focused on symptom management for diarrhoea, constipation, or PPE. Although diarrhoea is addressed by only ONS (2009, 2014) and UKONS (2013), symptom protocols for diarrhoea were provided by five clinical sites. In general, consensus was found across the guidelines and local protocols with respect to diarrhoea assessment and management. These recommendations were consistent with the guideline published by ASCO (Benson et al., 2004) . Two particular differences were noted among the local and national guidelines when compared to the ONS recommendations. Although codeine phosphate was identified by UKONS and the five clinical site protocols as a treatment for diarrhoea, it was not identified as an intervention for diarrhoea by ONS (2009). Also, in 2009, ONS assigned budesonide to the 'effectiveness not established' category. However, this medication features in the symptom management protocols of four clinical sites for the treatment of severe diarrhoea. This review found a limited number of guidelines and symptom protocols available on constipation. Only one clinical site provided a symptom protocol although information related to self-care for constipation was available from four clinical sites. Similarly, a dearth of CPGs/EBRs focused on symptom management for PPE and perhaps not unrelated a symptom management protocol was provided by only one clinical site. Of note, consideration of pyridoxine was recommended by both UKONS (2013) and a clinical site protocol. However, this medication was assigned to the category of 'not recommended for practice' by the ONS.
FN and infection was the subject of only two papers from the published literature review. Both papers were literature reviews and one was a Cochrane review . This finding is likely due to the inclusion criteria which focused exclusively on the symptom management and self-care strategies for FN and infection in patients diagnosed with BC, CRC, NHL, or HL. Most likely reflecting the potentially life threatening nature of infection in patients with cancer (Pathak et al., 2015) , a number of CPGs/EBRs address FN and infection. Symptom protocols were developed by the clinical sites and, in the main, the guidance across all of these guidelines and protocols is consistent for both the assessment and management of patients presenting with FN/suspected neutropenic sepsis. The guidelines all conveyed the importance of a comprehensive history and assessment and the delivery of appropriate treatment based on the risk category identified. Broad consistency was found with respect to the prophylactic measures recommended for infection prevention.
The review of the published literature located two papers on symptom management interventions for pain. Both papers focused on exercise for pain in women receiving treatment for BC and while this intervention appears promising, more high quality studies are needed. Overall, pain is well addressed by CPGs/EBRs. In contrast to this finding, only one clinical site provided a symptom management protocol for pain. As this protocol was developed for the purpose of telephone triage, a greater focus was placed on the assessment of pain rather than interventions for pain management. Brief self-care advice was available from another clinical site. A general consensus was found across all of the international guidelines regarding the approach to pain assessment and management. Recommendations included the use of both pharmacological and nonpharmacological strategies and the importance of managing common side effects. The guidelines are broadly in line with the World Health Organisation (WHO) analgesic ladder which advocates a sequential progression from non-opioids to weak opioids to strong opioids. However, more recently the NCCN (2014) suggested the use of opioids for all levels of pain including mild pain. The importance of providing psychosocial support and education to the patient and family was recommended.
Limitations
The main limitation of this review is the lack of empirical research retrieved for the assessment and management of diarrhoea, constipation and PPE, in particular. This deficit may be due to the fact that the published literature search was confined to those studies where symptom assessment, management, or self-care was identified as a primary outcome. In addition, limiting the search to three databases and including only those studies published in English and undertaken over the previous ten year period (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) may explain the dearth of studies for these symptoms. The conduct of a recent literature review 3 and time constraints imposed by internal study deadlines informed the decision to limit the search to three databases and to include only those studies conducted in the previous ten years. That said, this scoping review includes seven literature reviews (including four SR) and recently updated CPGs/EBRs from leading international medical and nursing cancer organisations. The studies included in this review were not critically appraised as a scoping review does not set out to determine the quality of evidence, rather it seeks to examine as comprehensively as possible the published and grey literature relevant to the research question (Arksey and O' Malley, 2005) . Finally, information on symptom management protocols and self-care guidance was available from just over 40% of the participating clinical sites. Of note, while this scoping review included a consultation exercise with clinicians and patients at each of the participating clinical sites and with clinicians working with National Health Service (NHS) 24) (Scotland's national telehealth and telecare organisation), the data from this exercise are not reported here due to the word count limit.
Conclusions
Guidance for symptom management of the most common CRTs varies across the published and grey literature. Six-month post-intervention follow-up of (2007a) study evaluating impact of aerobic exercise training (AET) and resistance exercise intervention (RET) on fatigue (secondary endpoint).
Instrument(s): FACT-An
Participants who indicated adherence to both AET and RET during follow-up period reported improved levels of fatigue (p=.013). Limitations: reliance on self-reporting, differential loss to follow-up amongst groups and failure to acquire follow up data of objective end points. Courneya et al. (2009) Case rate for fatigue was 24% after surgery and 31% at end of treatment, although it was persistent for some at 6 months (11%) and 12 months (6%). Persistent CRF predicted by tumour size. CRF associated with significant disability and healthcare utilization. Limitations: not all patients participated in the main cohort and estimate of incidence at 5 years was cross-sectional and did not assess potential confounding clinical factors such as cancer recurrence. Ligibel et al. (2010) 1996) Patterns of change in fatigue levels did not differ between exercisers and nonexercisers, yet non-exercisers reported higher fatigue levels throughout the third cycle of chemotherapy. Limitations: homogenous sample, absence of baseline measurement for comparison and acknowledgment that daily diary may not fully reflect symptom experience. : N=99; patients with stage 1-1V colorectal cancer who experienced oral mucositis (OM) (WHO ≥grade 2) while receiving the first cycle of chemotherapy (primary treatment modality)
Oral mucositis (OM)
Multicentre RCT (B1)
To evaluate the safety and efficacy of high dose and low dose recombinant human intestinal trefoil factor (rhITF) vs placebo as a topical oral spray for the prevention and treatment of OM. Instrument(s): WHO OM Grading Scale and Oral Mucositis Assessment Scale (OMAS)
High dose rhITF and low dose rhITF significantly reduced the incidence and severity of OM. Particular benefit was observed 7-14 days after commencement of chemotherapy. Limitations: small sample size which likely resulted in the low frequency of grade 3-4 mucositis, therefore; the impact of rhITF in this higher-risk group can only be inferred. Nausea Lee et al. (2008) N=112; patients with stages 1 to 111 BC commencing their first cycle of adjuvant chemotherapy Secondary data analysis of a longitudinal, multicentre, RCT (tested the effectiveness of a systematic exercise intervention for CRF and associated symptoms including nausea) (B3)
To determine the relationship between nausea intensity and a moderate level of aerobic exercise during and after adjuvant cancer treatment. Instrument(s): Nausea intensity (0-10 numeric scale), exercise status and Karnofsky Performance Scale (KPS) were measured through patient self-report. Data collected at three time-points.
Although generally low for all participants, nausea intensity was lower for exercisers than for non-exercisers (p=.03) at T2 (end of adjuvant chemotherapy) while baseline (T1) and end of study (T3) nausea intensity scores did not differ significantly between the groups. Limitations: unidimensional measurements of nausea, infrequent exercise status measurements, non-measurement of nausea intensity during chemotherapy and inability to determine if T1 nausea was anticipatory or delayed. To describe the incidence and intensity of chemotherapy induced vomiting (CIV) for BC since the advent of 5-HT3 antagonists. Instrument(s): Daily log consisting of the three-item Despite the use of 5-HT3 antagonists, both acute and delayed CIV continue to be a problem for some BC patients (younger age, higher BMI, minority women). vomiting experience subscale from Rhodes Index of Nausea, Vomiting and Retching (INVR) Demographic and clinical questionnaires Although likely to be beneficial for those experiencing more CIV, few medication changes (8%) were made between cycles. Limitations: study sites may have been those where vomiting was a particular problem, participants only followed over two cycles of chemotherapy. Note: study undertaken prior to use of neurokinin 1 receptor antagonists. Nausea and Vomiting Fernandez-Ortega et al. Patients receiving high or moderate CINV regimens experienced significant nausea (31%) and vomiting (45%) despite administration of optimal antiemetic prophylaxis and both symptoms negatively impacted on their QoL. Limitations: real incidence of nausea may be less as self-administered questionnaire may have overestimated this symptom. Note: study undertaken prior to use of neurokinin 1 receptor antagonists. Pain Tatham et al. (2013) : 6 studies (4 RCTs, 2 Case Series)
Systematic review (A2)
To determine whether exercise therapy is more effective than no therapy in reducing shoulder pain for women undergoing treatment of BC, as well as to identify which exercise type is most effective and appropriate outcome measures to assess shoulder pain. Searches undertaken in PEDro, CINAHL, PubMed, Ovid MEDLINE and AMED, for relevant publications up to and including April 2011.
Exercise may be beneficial in reducing shoulder pain related to BC treatment but more high quality studies are warranted. Valid outcome measures such as the Brief Pain Inventory (BPI) and the visual analogue scale (VAS) appear effective in evaluating patients with shoulder pain and monitoring the initial and long-term effects of treatment plans. Limitations: low number of relevant studies and low methodological quality of studies. Amara (2008) :
Peripheral Neuropathy (CIPN)
3 studies identified (Clinical trials)
Literature review (A2)
To evaluate the role of glutamine in the reduction of chemotherapy induced peripheral neuropathy (CIPN). PubMed searched for primary studies (1990 ( -May 2008 .
Two studies reported that oral glutamine was effective in decreasing CIPN associated with high dose paclitaxel while another study found it effective for CIPN in patients with colorectal cancer being treated with oxaliplatin. However, larger, well designed placebo controlled RCTs need to be conducted. Limitations: Non SR conducted through PubMed only; also, methodological limitations of the studies reviewed. Speck et al. (2012) :
N=25; patients with BC who had received at least two cycles of taxane-based chemotherapy. Either currently or within 6 months of treatment (neoadjuvant, adjuvant, metastatic) (stratified to ensure half with and without documented CIPN)
Descriptive qualitative study (B3)
To explore the self-management strategies utilized by female BC patients to cope with the impact of CIPN. Data collected via semi-structured interviews and patient level data.
Various self-management strategies employed to manage symptoms of CIPN including exercise, mindfulness, occupational therapy, and environmental planning. Limitations: potential for misclassification, information bias and issue of generalisability.
Wang et al. To assess the efficacy of oral glutamine (15g twice a day for seven days every two weeks) for preventing CIPN in patients receiving oxaliplatin for MCRC. Instrument(s): National Cancer Institute Common Toxicity Criteria (NCI-CTC) and various neurological assessments A significantly lower incidence of both grade 1-2 CIPN after chemotherapy cycle 2 (p=.04) and grade 3-4 CIPN after cycles 4 (p=.05) and 6 (p=.04) in the glutamine group. Limitations: non-placebo controlled, unblinded and relatively small sample size. Although the prevalence of physical symptoms not specific to chemotherapy (constipation, insomnia, dyspnea, pain) were high, they were less likely to be recognized by ON than symptoms associated with chemotherapy, such as fatigue and appetite loss. Overall, nurses' awareness of their patients' supportive care needs, physical and psychological nurses (ON), based in outpatient chemotherapy units with a mean of 10 years' experience as a nurse.
Multiple Symptoms
ON were blinded to their patients' questionnaire responses and were asked to complete a nurse questionnaire assessing the same endpoints. symptoms were less than optimal in routine care. Limitations: Potential selection bias, different assessment measures for patients and nurses may have influenced results. Nurse related contextual issues (e.g. workload/rapport) may have impacted on accuracy but were not investigated. O'Shaughnessy (2007) Patients receiving adjuvant treatment for BC.
Literature review (A2)
To discuss new guidelines for the supportive treatment of patients undergoing adjuvant treatment for BC and to evaluate novel strategies that can be used to improve the safety of these highly effective regimens. Review focused on febrile neutropenia (FN)/infection and cardiac toxicity.
The NCCN and ASCO guidelines for colony stimulating factor (CSF) use now recommend routine CSF factor administration with cycle one for chemotherapy regimens associated with a ≥ 20% risk of FN or in high risk patients even if risk associated with regimen is < 20%. Limitations: Non SR; methodological limitations of the studies reviewed. Smithies et al., (2009 To assess the value of, and perceived need for a telephone call to BC patients on the weekend following the initiation of chemotherapy. Instruments: Telephone questionnaire (incorporating a comprehensive list of possible side effects). Demographic and oncology physician questionnaire to document number and nature of calls from patients.
All participants clearly indicated that a telephone call shortly after the initiation of treatment can be beneficial with regard to teaching and/or reminding them about whom to contact for help. Conversely, the physicians did not see the need for such an intervention. Limitations: small sample size, limited generalizability, sample homogeneity and data entry was by same person who conducted the telephone intervention. :
Patients receiving chemotherapy for colorectal cancer. Four randomized studies involving a total of 342 patients.
Cochrane review (A1)
To assess the effect of herbal medicines on chemotherapy-related side effects, quality of life and objective measures of immune function. Searches conducted on Cochrane Library, MEDLINE, EMBASE, Chinese Biomedical Base and a hand search of Chinese journals ranging from 1966-2003. Compared with patients treated with chemotherapy alone, patients treated with chemotherapy and Huangqi decoctions were less likely to experience nausea and vomiting or low white cell counts and there was no evidence of harm from their use. Limitations: available studies were limited in number, small in size and of low quality. Authors noted that chemotherapy regimens used in the studies were not typical of those used worldwide.
*Typology of the level of evidence (adapted from UK Department of Health)
Appendix 3: Description of grey literature Note: it is likely that some of the symptom protocols did not list all of the medications that may have been used subsequently, in particular where guidelines were developed for the purpose of telephone triage. Oral intake decreased without significant weight loss, dehydration or malnutrition Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated Review prescribed antiemetic regimen (5, 6, a, b, d, e, f) Advise to: take small frequent sips of fluids (6, a, b, d, f), eat small frequent amounts of foods (5, 6, a, b, d, f), avoid spicy, fatty foods (5, b, d, f ), avoid strong odours (5, b, d, f), try ginger biscuits/foods/fluids (6, a, b, d, f ), take antiemetics prior to meals (5, a) and monitor for signs of dehydration ( 6, a) Consider non-pharmacological therapies such as acupuncture/acupressure (5, b, d, f), music therapy (5, a), relaxation/progressive muscle relaxation (1, 4, 5, a, b, f), behavioural therapy with systematic desensitisation for anticipatory CINV (1, 2, 4) Present to hospital for immediate review (6, a, b, d, e) Table 7 Chemotherapy induced peripheral neuropathy (grey literature) CIPN (symptom management and self-care advice) International Cancer Organisations clinical practice guidelines/evidenced based resources (2: American Society for Clinical Oncology (ASCO); 5: Oncology Nursing Society (ONS); 7: European Oncology Nursing Society (EONS)) And local clinical site protocols (grey literature) (Clinical sites: a, b, c, d , e, f) Assessment
Symptom Management
Comprehensive baseline assessment identifying co-morbidities (2, 7, a) with neurological impact placing patients at higher risk (2,7) Treatment to date (7, a), identifying other neurotoxic treatments received (7) Determine grade of symptom (2, 7, a) Identify all medications taken (7, a) (including non-prescribed), supplements (7) Neurological assessment (7); assess falls risk (7) 
Duloxetine (2, 5) Tricyclic antidepressants (e.g., nortriptyline or desipramine) (2, 5); gabapentin (2, 5) and a topical gel treatment containing baclofen (10 mg), amitriptyline HCL (40 mg), and ketamine (20 mg) (2). (It is reasonable to consider all three agents in the context of limited treatment options for CIPN and having discussed with patients the potential harms, benefits and costs (2). Consider dose reduction or stopping treatment (7) Education and support to preserve patient safety (7) Consider referral to rehabilitation specialist (7) Assist patients to identify solutions to deal with changes/problems with ADLs/household duties and changes/problems at work (7) Educate on principles of foot care and approaches to reduce risk of ischaemic or thermal injury in extremities; avoid exposure to cold (7). Educate on strategies to prevent symptoms of autonomic dysfunction (e.g. dangling legs prior to standing / adequate fluid intake) (7). Advise regarding reporting symptom; reassure that CIPN is an expected side effect of treatment (a, b) Grade 4: Present to hospital for immediate review (a) *Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0). Severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self-care ADL -----------------
Reassurance (6), emphasise importance of skin care regime/regular moisturiser (6, c), advise to contact if symptom worsens (6), consider pyridoxine as per local policy (6, c) for patients on capecitabine, 5FU or liposomal doxorubicin Discuss withholding treatment with medical team until resolved to grade 0-1 (6), emphasise importance of skin care regime (6, c), consider pyridoxine as per local policy (6, c) Inform medical team and stop medication until resolved to grade 0-1 (6) (5) review analgesia and consider paracetamol if indicated (6), emphasise importance of skin care regime (6, c), consider pyridoxine as per local policy (6, c) *Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).
